Protalix posted a slight revenue decline in Q3 2025 but remained profitable, supported by stable sales across its partners and increased R&D investments.

Protalix BioTherapeutics reported a net income of $164,000 for Q2 2025, a significant improvement from a net loss of $2.2 million in the same period last year. Total revenue increased to $15.658 million, driven by strong sales of Elfabrio to Chiesi, despite decreases in sales to Fiocruz (Brazil) and Pfizer. The company also saw a substantial increase in research and development expenses due to preparations for the PRX-115 Phase 2 clinical trial.

Protalix BioTherapeutics reported a solid first quarter in 2025 with a significant increase in revenues from selling goods. The company is focused on advancing its gout candidate, PRX-115, into a phase II clinical trial later this year, following promising phase I results.

Protalix BioTherapeutics delivered a solid Q4-24, driven by strong product sales to Chiesi, Pfizer, and Brazil. The company repaid all outstanding debt and strengthened its balance sheet. Net income improved despite lower license and R&D service revenue.

Protalix BioTherapeutics reported a strong third quarter with a 75% increase in revenue from selling goods, primarily due to increased sales to Chiesi and Pfizer. The company also made progress with its PRX-115 clinical trial for uncontrolled gout, with encouraging preliminary results from the Phase I study.

Protalix BioTherapeutics reported financial results for the second quarter ended June 30, 2024. The company recorded revenues from selling goods of $13.3 million, a decrease of $1.8 million compared to the same period last year. The company's net loss for the quarter was approximately $2.2 million, or $0.03 per share.

Protalix BioTherapeutics reported a net loss of $4.6 million for Q1 2024, compared to a net loss of $3.1 million for the same period in 2023. Revenues decreased to $3.748 million from $9.588 million year-over-year, primarily due to lower sales to Pfizer and Brazil, and the completion of R&D services related to Elfabrio.

Protalix BioTherapeutics reported a successful fiscal year 2023, marked by the regulatory approval of Elfabrio in multiple regions and progress in its clinical pipeline, including PRX-115 for severe gout. The company's financial performance showed increased revenues and a shift to net income, positioning it for future growth.

Protalix BioTherapeutics reported revenues from selling goods of $10.2 million during the three months ended September 30, 2023, an increase of $1.4 million, or 16%, compared to revenues of $8.8 million for the three months ended September 30, 2022. Net loss for the three months ended September 30, 2023 was approximately $1.9 million, or $0.03 per share, basic, and $0.04 per share, diluted, compared to a net loss of $3.6 million, or $0.07 per share, basic and diluted, for the same period in 2022.

Protalix BioTherapeutics reported a strong second quarter in 2023, marked by regulatory approvals for Elfabrio in the U.S. and EU, leading to a significant increase in revenues and a net income of $19.3 million, a substantial improvement compared to the net loss in the same period last year.

Protalix BioTherapeutics reported a decrease in revenue and a net loss for the first quarter of 2023. The company is awaiting decisions from the European Commission and the FDA regarding PRX-102 and is progressing with the PRX-115 program.

Protalix BioTherapeutics reported financial results for the fiscal year ended December 31, 2022. The company saw an increase in revenues from selling goods, driven by higher sales to Pfizer, Brazil, and Chiesi. Revenue from licenses and R&D services also increased slightly. The company's net loss decreased compared to the previous year.

Protalix BioTherapeutics reported its Q3 2022 financial results, highlighted by a significant increase in revenue from selling goods, driven by higher sales to Pfizer and Chiesi, which was partially offset by decreased sales to Brazil. Revenue from licenses and R&D services decreased. The company resubmitted its BLA to the FDA for PRX-102. Net loss decreased compared to the same period in 2021.

Protalix BioTherapeutics reported financial results for the second quarter ended June 30, 2022. The company recorded revenues from selling goods of $3.4 million and revenue from licenses and R&D services of $5.4 million. Net loss for the quarter was approximately $5.3 million, or $0.11 per share.

Protalix BioTherapeutics reported a strong first quarter with a 100% increase in revenue from selling goods and a significant reduction in net loss. Positive clinical trial results for PRX-102 and regulatory advancements in Europe highlight the company's progress in treating Fabry disease.

Protalix BioTherapeutics reported its financial results for the fiscal year ended December 31, 2021. The company's revenue from selling goods increased slightly, while revenue from licenses and R&D services decreased. Operating loss and net loss were reported for the year.

Protalix BioTherapeutics reported its Q3 2021 financial results, showing an increase in revenues from selling goods by 36% compared to the same period in 2020. Revenues from license and R&D services remained consistent. The company's net loss for the quarter was $4.2 million, slightly better than the $4.4 million loss in Q3 2020. The company is progressing with its regulatory submissions for PRX-102 and has sufficient capital to fund operations through milestones in 2022.

Protalix BioTherapeutics reported financial results for the second quarter ended June 30, 2021. The company is working closely with the FDA to address issues raised in the Complete Response Letter for PRX-102. They strengthened their balance sheet through agreements with note holders, reducing debt and extending maturity.

Protalix BioTherapeutics reported a net loss of $5.5 million for the first quarter of 2021, compared to a net income of $1.7 million for the same period in 2020. Total revenue decreased by 47.7% to $11.32 million, driven by a decrease in sales to Brazil and a decrease in license and R&D services revenue.

Protalix BioTherapeutics reported full year 2020 financial results, featuring revenue from selling goods of $16.2 million and revenue from licenses and R&D services of $46.7 million. The company's net loss for the year was $6.5 million, or $0.22 per share.

Protalix BioTherapeutics reported financial results for the third quarter ended September 30, 2020. The company recorded revenues from selling goods of $3.3 million and revenues from license and R&D services of $7.5 million.

Protalix BioTherapeutics reported revenues from selling goods of $3.6 million and revenues from license and R&D services of $7.3 million for the second quarter ended June 30, 2020. The company also announced positive topline results in its BRIDGE phase III clinical trial of PRX-102 for the treatment of Fabry disease and subsequent BLA submission to the U.S. Food and Drug Administration (FDA).

Protalix reports a transformational first quarter in 2020, closing a $43.7 million private placement and submitting a BLA for PRX-102 after completing the Phase III BRIDGE study.

Protalix reported financial results for the fourth quarter and full year ended December 31, 2019. The company is focused on advancing its clinical pipeline, expanding sales in Brazil of Elelyso®, and leveraging commercial opportunities to expand its global footprint in the treatment of Fabry disease.